Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.97 |
| ▸ | CA1 | P00915 | 18/20 | 0.97 |
| ▸ | CA9 | Q16790 | 14/20 | 0.97 |
| ▸ | CA4 | P22748 | 13/20 | 0.97 |
| ▸ | CA12 | O43570 | 10/20 | 0.97 |
| ▸ | CA3 | P07451 | 10/20 | 0.97 |
| ▸ | CA6 | P23280 | 10/20 | 0.97 |
| ▸ | CA5A | P35218 | 10/20 | 0.97 |
| ▸ | CA7 | P43166 | 10/20 | 0.97 |
| ▸ | CA13 | Q8N1Q1 | 10/20 | 0.97 |
| ▸ | CA14 | Q9ULX7 | 10/20 | 0.97 |
| ▸ | CA5B | Q9Y2D0 | 10/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359112 | 0.93 | CA1 (0.83) | CA2CA1CA9CA4CA12 | |
| SCHEMBL13740942 | 0.88 | CA2 (1.00) | CA2CA1CA9CA4CA12 | |
| SCHEMBL22118542 | 0.88 | CA1 (0.80) | CA2CA1CA9CA4CA12 | |
| SCHEMBL30721294 | 0.86 | CA1 (0.76) | CA2CA1CA9CA4CA12 | |
| SCHEMBL19359120 | 0.84 | CA2 (0.77) | CA2CA1CA9CA4CA12 | |
| SCHEMBL27277706 | 0.84 | CA1 (0.73) | CA2CA1CA9CA4CA12 | |
| SCHEMBL26259445 | 0.84 | CA1 (1.00) | CA2CA1CA9CA4CA12 | |
| SCHEMBL27277713 | 0.83 | CA1 (0.71) | CA2CA1CA9CA4CA12 | |
| SCHEMBL3793947 | 0.82 | CA1 (1.00) | CA2CA1CA9CA4CA12 | |
| SCHEMBL18476520 | 0.81 | CA1 (0.78) | CA2CA1CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676538-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF CAIX-EXPRESSING TUMORS | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250352675-A1 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| EP-4562100-A2 | CA-IX TARGETING FLUORESCENT PROBES | Bracco Imaging SPA (IT) | 2025-06-04 | — | — | EP | disclosed |
| CN-119325492-A | CA-IX targeting fluorescent probes | 伯拉考成像股份公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024191887-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF CAIX-EXPRESSING TUMORS | PURDUE RESEARCH FOUNDATION (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024023138-A2 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING SPA (IT) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024023138-A2 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING SPA (IT) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024023144-A1 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING SPA (IT) | 2024-02-01 | — | — | WO | disclosed |
| WO-2017161195-A1 | CA IX-TARGET NIR DYES AND THEIR USES | On Target Laboratories, LLC (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161195-A1 | CA IX-TARGET NIR DYES AND THEIR USES | On Target Laboratories, LLC (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352675-A1 | CA-IX TARGETING FLUORESCENT PROBES | CA9, CA4, CA7 | CA2 8/4885CA1 9/4885CA9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.